Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c01903 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Lingying Leng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States. Hauptthemen laut MEDLINE: Transcription Factors, Nuclear Proteins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute, Oncopia Therapeutics, Inc..
Abstract (Originalsprache)
In the SWI/SNF chromatin-remodeling complex, the mutually exclusive catalytic ATPase subunits SMARCA2 and SMARCA4 proteins have a synthetic-lethal relationship. Selectively targeting SMARCA2 for degradation is a promising and new therapeutic strategy for human cancers harboring inactivated mutated SMARCA4. In this study, we report the design, synthesis, and biological evaluation of novel SMARCA2/4 ligands and our subsequent design of PROTAC degraders using high-affinity SMARCA ligands and VHL-1 ligands. Our efforts led to the discovery of high-affinity SMARCA2/4 bromodomain ligands and the development of a potent and selective SMARCA2 degrader and a highly potent SMARCA2/4 and PBRM1 degrader.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, United States.
- SK Life Science Laboratories, 2500 Renaissance Blvd, King of Prussia, Pennsylvania 19406, United States.
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States.
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States.
ORCID-Profile: Rohan Kalyan Rej, Jelena Tošović, Zhenwu Li, Shaomeng Wang
Förderung
- NCI NIH HHS
- National Cancer Institute
- Oncopia Therapeutics, Inc.
Zitieren
APA
Leng, L., Tu, W., Yang, L., Huang, L., Wang, M., Meagher, J. L., Chinnaswamy, K., Allu, S. R., Rej, R. K., Tošović, J., Harikrishnan, L., Li, Z., Sui, Z., Stuckey, J. A., & Wang, S. (2025). Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01903
Vancouver
Leng L, Tu W, Yang L, Huang L, Wang M, Meagher JL, et al. Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c01903
BibTeX
@article{Leng2025,
author = {Leng, Lingying and Tu, Wenbin and Yang, Lin and Huang, Liyue and Wang, Mi and Meagher, Jennifer L and Chinnaswamy, Krishnapriya and Allu, Srinivasa Rao and Rej, Rohan Kalyan and Tošović, Jelena and Harikrishnan, Lalgudi and Li, Zhenwu and Sui, Zhihua and Stuckey, Jeanne A and Wang, Shaomeng},
title = {Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c01903}
}
EUVIMED